Moderna hopes to market the combined COVID and Flu Booster in 2023. The booster will protect the RSV from single shots that will be operated before winter.
 |
| Moderna hopes to market combined COVID and flu booster in 2023 |
Moderna hopes to market a combined booster vaccine for COVID-19, influenza, and RSV - a common respiratory virus - in the fall of 2023, CEO Stephen Bancel said Monday.
Speaking at a panel at the World Economic Forum, Bancelsaid the combination vaccine would enable people to get comprehensive protection against respiratory viral infections before the winter infectious season without having to receive multiple jabs.
"Our goal is to be able to have a single annual booster so that we don't have a compliance problem where people don't want to get two to three shots in the winter," Bancel said. "The best situation would be the fall of 2023."
Related Article: The latest on the coronavirus pandemic and the Omicron variant
Bancel told investors last September that Moderna was working on a booster shot that would combine its mRNA vaccine for COVID-19, a vaccine it is developing against influenza, and possibly a drug for the treatment of respiratory syncytial virus or RSV.
Covid Booster is currently on a third-stage trial, he said in a panel discussion, while the developing flu vaccine - which also uses mRNA technology - should progress to three trials from Phase II in the second quarter. Investors sold Moderna shares after an update in December showed that it had created antibody levels against four strains of influenza virus in an early-stage study that was not as strong as Sanofi’s existing flu jab in the elderly.
Moderna plans to send 2 to 3 billion doses of the Covid-19 vaccine this year, with Bancel confirming that by 2021 it will be 807 million. The company is currently consulting with health officials about the dosage of the Covid-19 vaccine this fall.
0 Comments